JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
NLSN
2001
DELISTED
Nielsen Holdings plc
NLSN
| $10.9M | ﹤0.01% |
469,123
-674,869
| -59% | -$17.3M |
2013 Q2
36 quarters
|
|
2002
PUT
Royal Gold
RGLD
$19.7B
| $10.9M | ﹤0.01% |
+102,000
| New | +$12.6M |
2022 Q2
0 quarters
|
|
2003
PUT
Lucid Motors
LCID
$1.65B
| $10.9M | ﹤0.01% |
63,440
+36,510
| +136% | +$6.94M |
2021 Q1
5 quarters
|
|
|
EFC
2004
Ellington Financial
EFC
$1.51B
| $10.9M | ﹤0.01% |
741,855
-280,218
| -27% | -$4.39M |
2018 Q4
14 quarters
|
|
2005
B2Gold
BTG
$6.83B
| $10.9M | ﹤0.01% |
3,204,831
+861,208
| +37% | +$3.6M |
2013 Q2
36 quarters
|
|
|
UNVR
2006
DELISTED
Univar Solutions Inc.
UNVR
| $10.9M | ﹤0.01% |
436,761
+44,236
| +11% | +$1.3M |
2019 Q1
13 quarters
|
|
|
ODP
2007
DELISTED
ODP
ODP
| $10.8M | ﹤0.01% |
358,809
+1,280
| +0.4% | +$51.7K |
2013 Q2
36 quarters
|
|
2008
Byline Bancorp
BY
$1.68B
| $10.8M | ﹤0.01% |
455,442
-21,735
| -5% | -$525K |
2017 Q4
18 quarters
|
|
|
NVEI
2009
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
| $10.8M | ﹤0.01% |
299,602
+80,330
| +37% | +$4.19M |
2021 Q4
2 quarters
|
|
2010
Visteon
VC
$2.36B
| $10.8M | ﹤0.01% |
104,588
+17,672
| +20% | +$1.82M |
2013 Q2
36 quarters
|
|
2011
TriNet
TNET
$2.98B
| $10.8M | ﹤0.01% |
139,398
-117,699
| -46% | -$9.83M |
2014 Q2
32 quarters
|
|
2012
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.63B
| $10.8M | ﹤0.01% |
285,547
-223,121
| -44% | -$8.87M |
2017 Q1
21 quarters
|
|
2013
CALL
Thermo Fisher Scientific
TMO
$241B
| $10.8M | ﹤0.01% |
19,900
-59,300
| -75% | -$32.6M |
2021 Q2
4 quarters
|
|
|
ITCI
2014
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.8M | ﹤0.01% |
189,217
+32,073
| +20% | +$1.82M |
2017 Q3
19 quarters
|
|
|
UNIT
2015
Uniti Group
UNIT
$1.93B
| $10.8M | ﹤0.01% |
1,146,185
-231,755
| -17% | -$2.68M |
2015 Q2
28 quarters
|
|
2016
ProShares UltraPro QQQ
TQQQ
$38.3B
| $10.7M | ﹤0.01% |
894,762
+527,074
| +143% | +$9.35M |
2020 Q2
8 quarters
|
|
2017
BlueLinx
BXC
$580M
| $10.7M | ﹤0.01% |
160,588
+153,208
| +2,076% | +$11.5M |
2017 Q2
20 quarters
|
|
|
LCA
2018
DELISTED
Landcadia Holdings IV, Inc. Class A Common Stock
LCA
| $10.7M | ﹤0.01% |
1,095,000
+846,573
| +341% | +$8.28M |
2021 Q4
2 quarters
|
|
2019
LeMaitre Vascular
LMAT
$1.83B
| $10.7M | ﹤0.01% |
235,180
+72,611
| +45% | +$3.25M |
2016 Q3
23 quarters
|
|
|
CIVI
2020
DELISTED
Civitas Resources
CIVI
| $10.7M | ﹤0.01% |
204,657
+108,139
| +112% | +$7.06M |
2017 Q2
20 quarters
|
|
2021
Simmons First National
SFNC
$3.28B
| $10.7M | ﹤0.01% |
503,007
+16,303
| +3% | +$396K |
2013 Q2
36 quarters
|
|
2022
Choice Hotels
CHH
$4.6B
| $10.7M | ﹤0.01% |
95,688
+19,994
| +26% | +$2.6M |
2014 Q3
31 quarters
|
|
2023
Banner Corp
BANR
$2.47B
| $10.7M | ﹤0.01% |
189,979
-75,221
| -28% | -$4.2M |
2013 Q2
36 quarters
|
|
2024
Ternium
TX
$10.9B
| $10.7M | ﹤0.01% |
295,513
-36,782
| -11% | -$1.56M |
2015 Q4
26 quarters
|
|
2025
MillerKnoll
MLKN
$1.39B
| $10.6M | ﹤0.01% |
405,284
-53,358
| -12% | -$1.62M |
2013 Q2
36 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.